Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial.
Teresa MichiChiara MattanaLuca S MengaMaria Grazia BocciMelania CesaranoTommaso RosàMaria Rosaria GualanoJonathan MontomoliSavino SpadaroMatteo TosatoElisabetta RotaFrancesco LandiSalvatore L CutuliEloisa S TanzarellaGabriele PintaudiEdoardo PiervincenziGiuseppe BelloTommaso TonettiPaola RucciGennaro De PascaleSalvatore M MaggioreDomenico Luca GriecoGiorgio ContiMassimo Antonellinull nullPublished in: Journal of intensive care (2023)
In patients with COVID-19 hypoxemic respiratory failure, treatment with helmet NIV or high-flow oxygen yielded similar quality of life and functional outcome at 6 months. The need for invasive mechanical ventilation was associated with worse outcomes. These data indicate that helmet NIV, as applied in the HENIVOT trial, can be safely used in hypoxemic patients. Trial registration Registered on clinicaltrials.gov NCT04502576 on August 6, 2020.
Keyphrases
- respiratory failure
- mechanical ventilation
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- intensive care unit
- end stage renal disease
- positive airway pressure
- study protocol
- coronavirus disease
- newly diagnosed
- phase iii
- ejection fraction
- sars cov
- clinical trial
- chronic kidney disease
- randomized controlled trial
- phase ii
- prognostic factors
- peritoneal dialysis
- skeletal muscle
- sleep apnea
- adipose tissue
- open label
- machine learning
- artificial intelligence
- combination therapy
- smoking cessation